MedTech

Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?

January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the AI platform often…

ByByAnuja Singh Jan 26, 2026

Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?

Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson (J&J) is set…

ByByAnuja Singh Jan 26, 2026

Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?

January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…

ByByAnuja Singh Jan 26, 2026

Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?

23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…

ByByAnuja Singh Jan 24, 2026
Image Not Found

Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?

23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…

ByByAnuja Singh Jan 24, 2026

Is the U.S. Reopening the Door to Coverage Losses? ACA Subsidy Expiration Fuels Cost and Enrollment Uncertainty

23 January 2026 Executive Summary The expiration of enhanced Affordable Care Act (ACA) subsidies is continuing to drive…

ByByAnuja Singh Jan 24, 2026
Scroll to Top